



ASX Announcement

12 August 2020

Atomo to present at Canaccord's 40th Annual Growth Conference

SYDNEY Australia, 12 August 2020 – Atomo Diagnostics Limited (ASX: AT1) (**Atomo**) is pleased to announce that Atomo will present virtually at Canaccord's 40th Annual Growth Conference overnight tonight.

Atomo's presentation will be delivered by Co-founder and Managing Director, John Kelly and CFO, Will Souter **at 9.30am EST on 12 August 2020 (11.30pm AEST on 12 August 2020.)**

The presentation, which was released to the ASX on 11 August provides an overview of the current status of the business and the company's outlook, including its increasing focus on the North American market.

Analysts and portfolio managers that wish to attend the presentation or would like to request a meeting with Atomo should contact Canaccord Genuity directly.

For more information, please contact:

Jane Lowe
IR Department

jane.lowe@irdepartment.com.au

Phone: +61 411 117 774

John Kelly
Atomo

john.kelly@atomodiagnostics.com

This announcement was authorised by John Kelly, Managing Director.

About Atomo

Atomo is a world leader in medical device design and development, based in Sydney, Australia. The company specializes in creating integrated rapid diagnostic test (RDT) platforms for blood-based testing. The recipient of multiple international awards for innovation, Atomo's all-in-one *AtomoRapid*[™] handheld devices make it easy to test and screen for a range of infectious diseases and chronic conditions. Its patented devices simplify testing procedures and enhance usability for professional users and untrained self-testers.

See more at www.atomodiagnostics.com